OBJECTIVES: To examine acylcarnitine profiles in individuals with hypo- or hyperthyroidism, and determine whether any atypical acylcarnitine species identified would normalize with correction of thyroid status. DESIGN AND METHODS: Serum acylcarnitine levels were measured in hypo- and hyperthyroid subjects before and after treatment with thyroxine or thionamide therapy respectively. RESULTS: No discernible differences were observed in the serum acylcarnitine profiles between hypo-, hyper- and euthyroid states. CONCLUSIONS: Acylcarnitine profiles are relatively unremarkable in thyroid disease.
OBJECTIVES: To examine acylcarnitine profiles in individuals with hypo- or hyperthyroidism, and determine whether any atypical acylcarnitine species identified would normalize with correction of thyroid status. DESIGN AND METHODS: Serum acylcarnitine levels were measured in hypo- and hyperthyroid subjects before and after treatment with thyroxine or thionamide therapy respectively. RESULTS: No discernible differences were observed in the serum acylcarnitine profiles between hypo-, hyper- and euthyroid states. CONCLUSIONS:Acylcarnitine profiles are relatively unremarkable in thyroid disease.
Authors: Maik Pietzner; Beatrice Engelmann; Tim Kacprowski; Janine Golchert; Anna-Luise Dirk; Elke Hammer; K Alexander Iwen; Matthias Nauck; Henri Wallaschofski; Dagmar Führer; Thomas F Münte; Nele Friedrich; Uwe Völker; Georg Homuth; Georg Brabant Journal: BMC Med Date: 2017-01-09 Impact factor: 8.775